Cognitive changes in patients with acute phase psychosis-Effects of illicit drug use

Psychiatry Research

Volumn 220, Issue 3, 2014, Pages 818-824

  Helle, Siri ^a   Gjestad, Rolf ^a   Johnsen, Erik ^a,b   Kroken, Rune Andreas ^a   Jørgensen, Hugo A ^b   Løberg, Else Marie ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Cognition; Neuropsychology; Psychotic disorders; Schizophrenia; Substance abuse

Indexed keywords

ILLICIT DRUG; STREET DRUG;

ACUTE PSYCHOSIS; ADULT; ARTICLE; COGNITION; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; LATENT GROWTH CURVE MODEL; MAJOR CLINICAL STUDY; MALE; NON AFFECTIVE PSYCHOSIS; PSYCHIATRIC DEPARTMENT; PSYCHOLOGIC TEST; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; ACUTE DISEASE; COGNITION DISORDERS; DRUG EFFECTS; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; PSYCHOLOGY; PSYCHOTIC DISORDERS; SINGLE BLIND PROCEDURE; YOUNG ADULT;

ACUTE DISEASE; ADULT; COGNITION; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; SINGLE-BLIND METHOD; STREET DRUGS; YOUNG ADULT;

EID: 84909972295     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.08.062     Document Type: Article

References (94)

1. Andreasson S., Allebeck P., Engstrom A., Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987, 2:1483-1486.
2. Bahorik A.L., Newhill C.E., Eack S.M. Neurocognitive functioning of individuals with schizophrenia: using and not using drugs. Schizophrenia Bulletin 2013, 40(4):856-867.
3. Bahorik A.L., Newhill C.E., Queen C.C., Eack S.M. Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors. Psychological Medicine 2014, 44:61-69.
4. Barch D.M., Carter C.S. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophrenia Research 2005, 77:43-58.
5. Barnett J.H., Croudace T.J., Jaycock S., Blackwell C., Hynes F., Sahakian B.J., Joyce E.M., Jones P.B. Improvement and decline of cognitive function in schizophrenia over one year: a longitudinal investigation using latent growth modelling. BMC Psychiatry 2007, 7. http://dx.doi.org/10.1186/1471-244X-7-16.
6. Bartels C., Wegrzyn M., Wiedl A., Ackermann V., Ehrenreich H. Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testing. BMC Neuroscience 2010, 11:118.
7. Beglinger L.J., Gaydos B., Tangphao-Daniels O., Duff K., Kareken D.A., Crawford J., Fastenau P.S., Siemers E.R. Practice effects and the use of alternate forms in serial neuropsychological testing. Archives of Clinical Neuropsychology: The Official Journal of the National Academy of Neuropsychologists 2005, 20:517-529.
8. Bersani G., Orlandi V., Gherardelli S., Pancheri P. Cannabis and neurological soft signs in schizophrenia: absence of relationship and influence on psychopathology. Psychopathology 2002, 35:289-295.
9. Blanchard J.J., Brown S.A., Horan W.P., Sherwood A.R. Substance use disorders in schizophrenia: review, integration, and a proposed model. Clinical Psychology Review 2000, 20:207-234.
10. Bollen K.A., Curran P.J. Latent Curve Models: A Structural Equation Perspective 2006, Wiley-Interscience, N.J.
11. Bossong M.G., Niesink R.J. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Progress in Neurobiology 2010, 92:370-385.
12. Brewer W.J., Francey S.M., Wood S.J., Jackson H.J., Pantelis C., Phillips L.J., Yung A.R., Anderson V.A., McGorry P.D. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. The American Journal of Psychiatry 2005, 162:71-78.
13. Callaghan R.C., Cunningham J.K., Allebeck P., Arenovich T., Sajeev G., Remington G., Boileau I., Kish S.J. Methamphetamine use and schizophrenia: a population-based cohort study in California. The American Journal of Psychiatry 2012, 169:389-396.
14. Cohen J., Cohen P., West S.G., Aiken L.S. Applied Multiple Regression-Correlation Analysis for the Behavioral Sciences 2003, Lawrence Erlbaum Associates, New York. 3 ed.
15. Cunha P.J., Rosa P.G., Ayres Ade M., Duran F.L., Santos L.C., Scazufca M., Menezes P.R., dos Santos B., Murray R.M., Crippa J.A., Busatto G.F., Schaufelberger M.S. Cannabis use, cognition and brain structure in first-episode psychosis. Schizophrenia Research 2013, 147:209-215.
16. Curran C., Byrappa N., McBride A. Stimulant psychosis: systematic review. The British Journal of Psychiatry: The Journal of Mental Science 2004, 185:196-204.
17. D'Souza D.C., Abi-Saab W.M., Madonick S., Forselius-Bielen K., Doersch A., Braley G., Gueorguieva R., Cooper T.B., Krystal J.H. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 2005, 57:594-608.
18. D'Souza D.C., Sewell R.A., Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. European Archives of Psychiatry and Clinical Neuroscience 2009, 259:413-431.
19. Di Forti M., Lappin J.M., Murray R.M. Risk factors for schizophrenia-all roads lead to dopamine. European Neuropsychopharmacology 2007, 17(Suppl. 2):S101-S107.
20. Di Forti M., Sallis H., Allegri F., Trotta A., Ferraro L., Stilo S.A., Marconi A., La Cascia C., Reis Marques T., Pariante C., Dazzan P., Mondelli V., Paparelli A., Kolliakou A., Prata D., Gaugrhan F., David A.S., Morgan C., Sthal D., Khondoker M., Maccabe J.H., Murray R.M. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophrenia Bulletin 2013, http://www.ncbi.nlm.nih.gov/pubmed/24345517.
21. Donoghue K., Doody G.A., Murray R.M., Jones P.B., Morgan C., Dazzan P., Hart J., Mazzoncini R., Maccabe J.H. Cannabis use, gender and age of onset of schizophrenia: data from the AESOP study. Psychiatry Research 2014, 215:528-532.
22. Drake R.E., Mueser K.T., McHugo G.J. Clinical rating scales: Alcohol Use Scale (AUS), Drug Use Scale (DUS), and Substance Abuse Treatment Scale (SATS). Outcomes Assessment in Clinical Practice 1996, 113-116. Williams & Wilkins, Baltimore. I.L. Sedere, B.E. Dickey (Eds.).
23. Drake R.E., Osher F.C., Noordsy D.L., Hurlbut S.C., Teague G.B., Beaudett M.S. Diagnosis of alcohol use disorders in schizophrenia. Schizophrenia Bulletin 1990, 16:57-67.
24. Duncan T.E., Duncan S.C. An introduction to latent growth curve modeling. Behavior Therapy 2004, 35:333-363.
25. Duncan T.E., Duncan S.C., Strycker L.A. An Introduction to Latent Variable Growth Curve Modeling: Concepts, Issues and Applications 2006, Lawrence Erlbaum, London. 2 ed.
26. Ferraro L., Russo M., O'Connor J., Wiffen B.D., Falcone M.A., Sideli L., Gardner-Sood P., Stilo S., Trotta A., Dazzan P., Mondelli V., Taylor H., Friedman B., Sallis H., La Cascia C., La Barbera D., David A.S., Reichenberg A., Murray R.M., Di Forti M. Cannabis users have higher premorbid IQ than other patients with first onset psychosis. Schizophrenia Research 2013, 150:129-135.
27. Gold J.M., Queern C., Iannone V.N., Buchanan R.W. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity. The American Journal of Psychiatry 1999, 156:1944-1950.
28. Goldberg T.E., Goldman R.S., Burdick K.E., Malhotra A.K., Lencz T., Patel R.C., Woerner M.G., Schooler N.R., Kane J.M., Robinson D.G. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Archives of General Psychiatry 2007, 64:1115-1122.
29. Goldberg T.E., Keefe R.S., Goldman R.S., Robinson D.G., Harvey P.D. Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2010, 35:1053-1062.
30. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. The American Journal of Psychiatry 1996, 153:321-330.
31. Gupta P., Mullin K., Nielssen O., Harris A., Large M. Do former substance users with psychosis differ in their symptoms or function from non-substance users? A systematic meta-analysis. The Australian and New Zealand Journal of Psychiatry 2013, 47:524-537.
32. Hausknecht J.P., Halpert J.A., Di Paolo N.T., Moriarty Gerrard M.O. Retesting in selection: a meta-analysis of coaching and practice effects for tests of cognitive ability. The Journal of Applied Psychology 2007, 92:373-385.
33. Helseth V., Lykke-Enger T., Johnsen J., Waal H. Substance use disorders among psychotic patients admitted to inpatient psychiatric care. Nordic Journal of Psychiatry 2009, 63:72-77.
34. Henquet C., Krabbendam L., Spauwen J., Kaplan C., Lieb R., Wittchen H.U., van Os J. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. British Medical Journal 2005, 330:11.
35. Henquet C., Rosa A., Krabbendam L., Papiol S., Fananas L., Drukker M., Ramaekers J.G., van Os J. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2006, 31:2748-2757.
36. Hobart M.P., Goldberg R., Bartko J.J., Gold J.M. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia, II: convergent/discriminant validity and diagnostic group comparisons. The American Journal of Psychiatry 1999, 156:1951-1957.
37. Holzer L., Chinet L., Jaugey L., Plancherel B., Sofia C., Halfon O., Randolph C. Detection of cognitive impairment with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) in adolescents with psychotic symptomatology. Schizophrenia Research 2007, 95:48-53.
38. Jimenez-Castro L., Raventos-Vorst H., Escamilla M. Substance use disorder and schizophrenia: prevalence and sociodemographic characteristics in the Latin American population. Actas Espanolas de Psiquiatria 2011, 39:123-130.
39. Johnsen E., Kroken R.A., Wentzel-Larsen T., Jørgensen H.A. Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry 2010, 10:26.
40. Karterud S., Pedersen G., Løvdahl H., Friis S. Global Assessment of Functioning-Split version (S-GAF): Background and Scoring Manual 1998, Ullevaal University Hospital, Department of Psychiatry, Oslo, Norway.
41. Kay S.R., Opler L.A., Lindenmayer J.P. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. British Journal of Psychiatry Supplements 1989, 59-67.
42. Keefe R.S., Fenton W.S. How should DSM-V criteria for schizophrenia include cognitive impairment?. Schizophrenia Bulletin 2007, 33:912-920.
43. Kline R.B. Principles and Practice of Structural Equation Modeling 2010, The Guilford Press, New York. 3 ed.
44. Kolb B., Robbin G. Brain plasticity and behaviour in the developing brain. Journal of Canadian Acadedemy of Child and Adolescent Psychiatry 2011, 20:265-276.
45. Koskinen J., Lohonen J., Koponen H., Isohanni M., Miettunen J. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophrenia Bulletin 2010, 36:1115-1130.
46. Kovasznay B., Fleischer J., Tanenberg-Karant M., Jandorf L., Miller A.D., Bromet E. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophrenia Bulletin 1997, 23:195-201.
47. Kuepper R., Morrison P.D., van Os J., Murray R.M., Kenis G., Henquet C. Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizophrenia Research 2010, 121:107-117.
48. Large M., Mullin K., Gupta P., Harris A., Nielssen O. Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use. The Australian and New Zealand Journal of Psychiatry 2014, 48:418-432.
49. Large M., Sharma S., Compton M.T., Slade T., Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Archives of General Psychiatry 2011, 68:555-561.
50. Leeson V.C., Harrison I., Ron M.A., Barnes T.R., Joyce E.M. The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia. Schizophrenia Bulletin 2012, 38:873-880.
51. Lewandowski K.E., Cohen B.M., Ongur D. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. Psychological Medicine 2011, 41:225-241.
52. Løberg E.M., Hugdahl K. Cannabis use and cognition in schizophrenia. Frontiers in Human Neuroscience 2009, 3:53.
53. Løberg E.M., Nygard M., Berle J.O., Johnsen E., Kroken R.A., Jørgensen H.A., Hugdahl K. An fMRI study of neuronal activation in schizophrenia patients with and without previous cannabis use. Frontiers in Psychiatry/Frontiers Research Foundation 2012, 3:94.
54. Margolese H.C., Malchy L., Negrete J.C., Tempier R., Gill K. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophrenia Research 2004, 67:157-166.
55. McKnight P.E., McKnight K.M., Sidani S., Figueredo A.J. Missing Data: a Gentle Introduction 2007, The Guilford Press, New York.
56. Meijer, J., Simons, C.J., Quee, P.J., Verweij, K., Investigators, G., 2012. Cognitive alterations in patients with non-affective psychotic disorder and their unaffected siblings and parents. Acta Psychiatrica Scandinavica 125, 66-76.
57. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
58. Mullin K., Gupta P., Compton M.T., Nielssen O., Harris A., Large M. Does giving up substance use work for patients with psychosis? A systematic meta-analysis. The Australian and New Zealand Journal of Psychiatry 2012, 46:826-839.
59. Muthén L.K., Muthén B.O. Mplus 5.2 2008, Muthén & Muthén, Los Angeles.
60. Muthén L.K., Muthén B.O. Mplus 7.11 2013, Muthèn & Muthèn, Los Angeles.
61. Myles N., Newall H., Nielssen O., Large M. The association between cannabis use and earlier age at onset of schizophrenia and other psychoses: meta-analysis of possible confounding factors. Current Pharmaceutical Design 2012, 18:5055-5069.
62. Nayak Savla G., Moore D.J., Roesch S.C., Heaton R.K., Jeste D.V., Palmer B.W. An evaluation of longitudinal neurocognitive performance among middle-aged and older schizophrenia patients: use of mixed-model analyses. Schizophrenia Research 2006, 83:215-223.
63. Palmer B.W., Dawes S.E., Heaton R.K. What do we know about neuropsychological aspects of schizophrenia?. Neuropsychology Review 2009, 19:365-384.
64. Pedhazur E.J., Schmelkin L.P. Measurement, Design, and Analysis: An Integrated Approach 1991, Lawrence Erlbaum Associates, Hillsdale, N.J.
65. Potvin S., Joyal C.C., Pelletier J., Stip E. Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophrenia Research 2008, 100:242-251.
66. Rabin R.A., Zakzanis K.K., Daskalakis Z.J., George T.P. Effects of cannabis use status on cognitive function, in males with schizophrenia. Psychiatry Research 2012, 206(2-3):158-165.
67. Rabin R.A., Zakzanis K.K., George T.P. The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophrenia Research 2011, 128:111-116.
68. Randolph C. RBANS Repeatable Battery for the Assessment of Neuropsychological Status 1998, The Psychological Corporation, San Antonio.
69. Raykov T. On estimating true change interrelationships with other variables. Quality and Quantitative 1993, 27:353-370.
70. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., Goodwin F.K. Comorbidity of mental disorders with alcohol and other drug abuse. Results From the Epidemiologic Catchment Area (ECA) Study. JAMA: The Journal of the American Medical Association 1990, 264:2511-2518.
71. Ringen P.A., Melle I., Birkenaes A.B., Engh J.A., Faerden A., Jonsdottir H., Nesvag R., Vaskinn A., Friis S., Larsen F., Opjordsmoen S., Sundet K., Andreassen O.A. Illicit drug use in patients with psychotic disorders compared with that in the general population: a cross-sectional study. Acta Psychiatrica Scandinavica 2008, 117:133-138.
72. Rodriguez-Sanchez J.M., Ayesa-Arriola R., Mata I., Moreno-Calle T., Perez-Iglesias R., Gonzalez-Blanch C., Perianez J.A., Vazquez-Barquero J.L., Crespo-Facorro B. Cannabis use and cognitive functioning in first-episode schizophrenia patients. Schizophrenia Research 2010, 124:142-151.
73. Royston P., Altman D.G., Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Statistics in Medicine 2006, 25:127-141.
74. Ruiz-Veguilla M., Callado L.F., Ferrin M. Neurological soft signs in patients with psychosis and cannabis abuse: a systematic review and meta-analysis of paradox. Current Pharmaceutical Design 2012, 18:5156-5164.
75. Salyers M.P., Mueser K.T. Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophrenia Research 2001, 48:109-123.
76. Sara G.E., Burgess P.M., Malhi G.S., Whiteford H.A., Hall W.C. Cannabis and stimulant disorders and readmission 2 years after first-episode psychosis. The British Journal of Psychiatry: The Journal of Mental Science 2014, 204(6):448-453.
77. Schmidt L.M., Hesse M., Lykke J. The impact of substance use disorders on the course of schizophrenia-a 15-year follow-up study: dual diagnosis over 15 years. Schizophrenia Research 2011, 130:228-233.
78. Sherwood M., Thornton A.E., Honer W.G. A meta-analysis of profile and time-course of symptom change in acute schizophrenia treated with atypical antipsychotics. The International Journal of Neuropsychopharmacology/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum 2006, 9:357-366.
79. Smith M.J., Thirthalli J., Abdallah A.B., Murray R.M., Cottler L.B. Prevalence of psychotic symptoms in substance users: a comparison across substances. Comprehensive Psychiatry 2009, 50:245-250.
80. SPSS IBM SPSS 20 (Version 20.0.0.1) 2011, IBM SPSS Statistics, Chicago.
81. Stirling J., Lewis S., Hopkins R., White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophrenia Research 2005, 75:135-137.
82. Stoolmiller M. Using latent growth curve models to study developmental processes. The Analysis of Change 1995, Lawrence Erlbaum Associates, N.J. J.M. Gottman, J.M. Collins (Eds.).
83. Szoke A., Trandafir A., Dupont M.E., Meary A., Schurhoff F., Leboyer M. Longitudinal studies of cognition in schizophrenia: meta-analysis. The British Journal of Psychiatry: The Journal of Mental Science 2008, 192:248-257.
84. Talamo A., Centorrino F., Tondo L., Dimitri A., Hennen J., Baldessarini R.J. Comorbid substance-use in schizophrenia: relation to positive and negative symptoms. Schizophrenia Research 2006, 86:251-255.
85. Tarricone I., Boydell J., Panigada S., Allegri F., Marcacci T., Minenna M.G., Kokona A., Triolo F., Storbini V., Michetti R., Morgan C., Di Forti M., Murray R.M., Berardi D. The impact of substance use at psychosis onset on First Episode Psychosis course: results from a 1 year follow-up study in Bologna. Schizophrenia Research 2014, 153:60-63.
86. Ventura J., Hellemann G.S., Thames A.D., Koellner V., Nuechterlein K.H. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophrenia Research 2009, 113:189-199.
87. International Statistical Classification of Diseases and Health Related Problems 2004, WHO, World Health Organization, Geneva.
88. Wilk C.M., Gold J.M., Bartko J.J., Dickerson F., Fenton W.S., Knable M., Randolph C., Buchanan R.W. Test-retest stability of the repeatable battery for the assessment of neuropsychological status in schizophrenia. The American Journal of Psychiatry 2002, 159:838-844.
89. Wilk C.M., Gold J.M., Humber K., Dickerson F., Fenton W.S., Buchanan R.W. Brief cognitive assessment in schizophrenia: normative data for the repeatable battery for the assessment of neuropsychological status. Schizophrenia Research 2004, 70:175-186.
90. Wobrock T., Falkai P., Schneider-Axmann T., Hasan A., Galderisi S., Davidson M., Kahn R.S., Derks E.M., Boter H., Rybakowski J.K., Libiger J., Dollfus S., Lopez-Ibor J.J., Peuskens J., Hranov L.G., Gaebel W., Fleischhacker W.W. Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study. Schizophrenia Research 2013, 147:132-139. E.s. group.
91. Woodberry K.A., Giuliano A.J., Seidman L.J. Premorbid IQ in schizophrenia: a meta-analytic review. The American Journal of Psychiatry 2008, 165:579-587.
92. Woodberry K.A., Seidman L.J., Giuliano A.J., Verdi M.B., Cook W.L., McFarlane W.R. Neuropsychological profiles in individuals at clinical high risk for psychosis: relationship to psychosis and intelligence. Schizophrenia Research 2010, 123:188-198.
93. Yucel M., Bora E., Lubman D.I., Solowij N., Brewer W.J., Cotton S.M., Conus P., Takagi M.J., Fornito A., Wood S.J., McGorry P.D., Pantelis C. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophrenia Bulletin 2012, 38:316-330.
94. Zammit S., Moore T.H., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., Lewis G. Effects of cannabis use on outcomes of psychotic disorders: systematic review. The British Journal of Psychiatry: The Journal of Mental Science 2008, 193:357-363.